Research Topics
| DANIEL ERIC FURSTSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Scleroderma--developing measures of responseDaniel E Furst
University of California at Los Angeles, CA 90025, USA
J Rheumatol 32:2477-80. 2005..Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma...- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007D E Furst
David Geffen School of Medicine, UCLA - RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA
Ann Rheum Dis 66:iii2-22. 2007 - Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are neededChristopher P Denton
Centre for Rheumatology, Royal Free Campus, University College Medical School, London, NW3 2PF, UK
Arthritis Res Ther 13:114. 2011..Failure to take this into account may compromise progress in managing PAH in SSc... - The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort studyMatthew L Mundwiler
North Suburban Rheumatologists, Des Plaines, IL 60016, USA
Arthritis Res Ther 11:R94. 2009..Similar analyses were performed for bone marrow edema, predicting a subsequent MRI erosion. Descriptive results of other lesions are reported... - Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005D E Furst
1000 Veteran Avenue Rehabilitation Centre, Room 32-59, Los Angeles, CA 90024, USA
Ann Rheum Dis 64:iv2-14. 2005 - A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritisDaniel E Furst
Department of Rheumatology, University of California at Los Angeles, California 90095, USA
J Rheumatol 32:2303-10. 2005..In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I, for the treatment of rheumatoid arthritis (RA)... - Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA?Daniel E Furst
Rheumatology at Geffen School of Medicine at UCLA, CA 90095 1670, USA
Nat Clin Pract Rheumatol 5:134-5. 2009.... - The risk of infections with biologic therapies for rheumatoid arthritisDaniel E Furst
University of California Los Angeles, Los Angeles, CA 90095 1670, USA
Semin Arthritis Rheum 39:327-46. 2010..To assess the risk of serious and nonserious bacterial and viral infections associated with the use of biologic therapy (abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab) in patients with rheumatoid arthritis (RA)... - Outcome measures in rheumatologic clinical trials and systemic sclerosisD E Furst
Geffen School of Medicine, University of California, Los Angeles, CA, USA
Rheumatology (Oxford) 47:v29-30. 2008..These include the echocardiogram, high-resolution CT scan of the lungs, pulmonary function tests, 6-min walking test and MRI... - Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panelD E Furst
Geffen School of Medicine, University of California at Los Angeles, 1000 Veteran Ave Rm 32 59, Los Angeles, CA 90095 1670, USA
Rheumatology (Oxford) 47:194-9. 2008..A panel of rheumatologists was convened to develop guidelines to assess adequacy of disease control, focusing on the use of disease-modifying anti-rheumatic drugs... - Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infectionDaniel E Furst
Department of Rheumatology, University of California at Los Angeles, Los Angeles, CA, USA
Semin Arthritis Rheum 36:159-67. 2006..Several reports indicate that the incidence of granulomatous infections may potentially be higher in individuals treated with INF than ETA... - Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006D E Furst
David Geffen School of Medicine, UCLA - RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA
Ann Rheum Dis 65:iii2-15. 2006 - Serum immunoglobulins and risk of infection: how low can you go?Daniel E Furst
University of California, Los Angeles, CA 90095 1670, USA
Semin Arthritis Rheum 39:18-29. 2009.... - Measuring outcomes in PAH: the gap between the measures that are used and their validityDaniel E Furst
Geffen School of Medicine at the University of California in Los Angeles, 1000 Veteran Avenue Room 32 59, Los Angeles, CA 90095, USA
Ann N Y Acad Sci 1107:410-6. 2007.... - Systemic sclerosis - continuing progress in developing clinical measures of responseDaniel Furst
University of California at Los Angeles, Los Angeles, California 90025, USA
J Rheumatol 34:1194-200. 2007..Another Delphi exercise is designed to develop consensus regarding a combined SSc response index to be validated in future RCT... - Stem cell transplantation for autoimmune disease: progress and problemsDaniel E Furst
UCLA Medical School, Rheumatology Division, Los Angeles, California 98101, USA
Curr Opin Rheumatol 14:220-4. 2002..In systemic sclerosis, criteria for patient selection and a limited number of stem cell transplantation regimens have been agreed on and controlled trials are underway... - Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritisDaniel E Furst
Rheumatology Division, Geffen School of Medicine, University of California Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90025 1670, USA
Clin Ther 26:1960-75. 2004..Inhibiting IL-1 synthesis or activity with the use of recombinant human IL-1 receptor antagonist (anakinra) may prove to be an effective approach to the treatment of RA... - Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst
Division of Rheumatology, Department of Medicine, University of California Los Angeles, CA 90095 1670, USA
Ann Rheum Dis 66:893-9. 2007..To incorporate a new trial design to examine clinical response, cytokine expression and joint imaging in patients with rheumatoid arthritis (RA) switching from etanercept to infliximab treatment... - Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging studyDaniel E Furst
University of California at Los Angeles Medical School, CA 90024, USA
Arthritis Rheum 46:2020-8. 2002..To assess the efficacy, safety, and optimal dose of tacrolimus monotherapy in patients with rheumatoid arthritis (RA)... - Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)D E Furst
University of California, Los Angeles, CA, USA
Ann Rheum Dis 61:ii2-7. 2002 - Double-blind, randomized, controlled, pilot study comparing classic ayurvedic medicine, methotrexate, and their combination in rheumatoid arthritisDaniel E Furst
Geffen School of Medicine, University of California Los Angeles, CA, USA
J Clin Rheumatol 17:185-92. 2011..To compare classic Ayurveda, methotrexate (MTX), and their combination in a double-blind, randomized, double-dummy, pilot trial in rheumatoid arthritis (RA) for 36 weeks... - Development of TNF inhibitor therapies for the treatment of rheumatoid arthritisDaniel E Furst
Geffen School of Medicine, University of California, Los Angeles, CA 90095 1670, USA
Clin Exp Rheumatol 28:S5-12. 2010.... - Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritisDaniel E Furst
Virginia Mason Research Center, Seattle, Washington, USA
J Rheumatol 30:2123-6. 2003..Efficacy variables included change from baseline in number of swollen joints and tender joints, scores on physician and patient assessments of disease activity, and patient assessment of pain... - Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)D E Furst
University of California, UCLA, Rheumatology, Division Los Angeles, USA
Ann Rheum Dis 62:ii2-9. 2003 - Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst
Division of Rheumatology, Department of Medicine, University of California Los Angeles, 32 59 Rehabilitation Center, 1000 Veteran Avenue, Box 951670, Los Angeles, CA 90095 1670, USA
J Rheumatol 30:2563-71. 2003..Standard antirheumatic therapy included traditional disease modifying antirheumatic drugs (DMARD), low dose corticosteroids, nonsteroidal antiinflammatory drugs (NSAID), and/or analgesics... - Acquired resistance of human T cells to sulfasalazineD E Furst
UCLA Medical School, 1000 Veteran Avenue, Rehabilitation Center, Room 32-59, Los Angeles, USA
Ann Rheum Dis 63:115-6. 2004 - Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registryD E Furst
University of California Los Angeles, Los Angeles, California, USA
Clin Exp Rheumatol 27:560-6. 2009.... - Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004D E Furst
University of California, Rheumatology Division, 1000 Veteran Avenue Rehabilitation Centre, Room 32-59, Los Angeles, CA 90024, USA
Ann Rheum Dis 63:ii2-ii12. 2004 - Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritisJeremy Sokolove
Stanford University, Palo Alto, CA, USA
Ann Rheum Dis 69:1612-7. 2010.... - Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung studyJonathan Goldin
Department of Radiologic Sciences, David Geffen School of Medicine, School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA
Chest 136:1333-40. 2009..This study examined thoracic high-resolution CT (HRCT) scans obtained during the SLS for treatment-associated changes over time... - Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyMichael H Weisman
Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Clin Ther 25:1700-21. 2003.... - Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trialsSogol Amjadi
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Arthritis Rheum 60:2490-8. 2009.... - Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung StudyDinesh Khanna
David Geffen School of Medicine, University of California, Los Angeles, USA
Arthritis Rheum 52:592-600. 2005.... - Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FASTNihal Fathi
David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Curr Rheumatol Rep 9:144-50. 2007.... - Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trialsKaren Au
Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Curr Rheumatol Rep 11:111-9. 2009..A randomized double-blind controlled trial by the Scleroderma Lung Study Research Group is currently comparing the efficacy and safety of mycophenolate mofetil versus oral cyclophosphamide... - Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna
David Geffen School at University of California, Los Angeles, CA, USA
J Rheumatol 36:2356-61. 2009..CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected... - High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 110:1388-96. 2007..Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies. HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial... - Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosisRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Arthritis Rheum 54:1982-6. 2006..To evaluate the safety and efficacy of allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning in patients with severe systemic sclerosis (SSc)... - Outcome measurements in scleroderma: results from a delphi exerciseHashim Gazi
Division of Rheumatology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada
J Rheumatol 34:501-9. 2007..To obtain a consensus on the minimal clinically relevant treatment effect in various scleroderma disease outcome measures to be used in future clinical trials... - Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?Dinesh Khanna
University of California, Los Angeles 90095, USA
Arthritis Rheum 50:1040-50. 2004 - Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot studyTien I Karleen Su
University of Southern California, Los Angeles, CA 90095 1670, USA
Arthritis Rheum 60:3821-30. 2009..To assess the safety and efficacy of rapamycin in the treatment of diffuse systemic sclerosis (SSc; scleroderma)... - Problems encountered during anti-tumour necrosis factor therapySheetal B Desai
Department of Rheumatology, University of California, Los Angeles, CA 90095 1670, USA
Best Pract Res Clin Rheumatol 20:757-90. 2006.... - Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritisHaoling H Weng
Amgen Inc, Thousand Oaks, California, USA
J Rheumatol 37:550-7. 2010..To evaluate responses by time to initiation of nonbiologic disease-modifying antirheumatic drugs (DMARD) in a DMARD-naive cohort of patients with early seropositive rheumatoid arthritis (RA)... - Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trialPuja P Khanna
Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
Rheumatology (Oxford) 49:955-9. 2010.... - Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA
J Rheumatol 32:832-40. 2005.... - Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trialsMarian Kaldas
UCLA Olive View, Sylmar, CA, USA
Rheumatology (Oxford) 48:1143-6. 2009..Our objective was to evaluate the sensitivity of change over time of individual body sites used in the calculation of total MRSS... - Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)Jan Storek
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
Clin Immunol 113:285-98. 2004..In conclusion, peripheral expansion of CD8 but not CD4 T cells is highly efficient. Prolonged CD4 lymphopenia is associated with relatively few infections, possibly due to antibodies produced by persisting pretransplant plasma cells... - Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosisPhilip J Clements
Department of Medicine, University of California, Los Angeles, 90095, USA
Arthritis Rheum 50:1909-17. 2004..This study was undertaken to investigate the utility of high-resolution computed tomography (HRCT) of the chest, in comparison with bronchoalveolar lavage (BAL), in the diagnosis of alveolitis in these patients... - Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung StudyDinesh Khanna
Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
Rheumatology (Oxford) 48:1537-40. 2009..Our objective was to assess minimally important difference (MID) for Mahler's Transition Dyspnoea Index (TDI) in SLS... - Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?Yolanda Braun-Moscovici
UCLA Medical School, Rheumatology Division, Los Angeles, California 98101, USA
Curr Opin Rheumatol 15:237-45. 2003.... - Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritisChristina Charles-Schoeman
David Geffen School of Medicine at University of California, Los Angeles, CA 90095 1670, USA
Arthritis Rheum 60:2870-9. 2009.... - Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosisVijay Bodukam
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Rheumatology (Oxford) 50:330-4. 2011..0 instrument; and (ii) to explore which GI-specific symptom scales are associated with depressed mood in patients with SSc... - Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entitiesRajeev Saggar
David Geffen School of Medicine at University of California, Los Angeles, CA 90095 1690, USA
Arthritis Rheum 62:3741-50. 2010..We undertook this study to describe the hemodynamic response to exercise in a homogeneous population of patients with scleroderma spectrum disorders at risk of developing pulmonary vascular disease... - Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trialsDinesh Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Clin Exp Rheumatol 28:S55-62. 2010..Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review... - High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements
Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA 90095 1670, USA
Semin Arthritis Rheum 33:249-63. 2004..To review important findings, or lessons, that were learned about measures of response, design, conduct, and analysis of a randomized, controlled trial (RCT), even though the trial failed to demonstrate efficacy of d-penicillamine... - Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot studyAimee M Hunter
Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles, CA, USA
Pain Med 10:730-8. 2009..We hypothesized that cordance might also predict response to antidepressant medications for symptoms of FMS... - Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract InstrumentDinesh Khanna
University of California, Los Angeles, CA, USA
Arthritis Rheum 61:1257-63. 2009..To refine the previously developed scleroderma (systemic sclerosis [SSc]) gastrointestinal tract (GIT) instrument (SSC-GIT 1.0)... - Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements
Divisions of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Ann Rheum Dis 66:1641-7. 2007..This report examines the differences at baseline and over 12 months between patients with limited versus diffuse cutaneous SSc who participated in the Scleroderma Lung Study... - Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot studyChristina Charles-Schoeman
Division of Rheumatology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, California 90095 1670, USA
J Rheumatol 34:1459-64. 2007..We examined the effects of atorvastatin 80 mg daily on the inflammatory properties of HDL and clinical disease activity in RA... - Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin
Department of Medicine, David Geffen School of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
Am J Respir Crit Care Med 176:1026-34. 2007..Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear... - Assessing disease progression using a composite endpointWeng Kee Wong
Department of Biostatistics, University of California at Los Angeles, CA, USA
Stat Methods Med Res 16:31-49. 2007..In addition, we propose desirability functions to monitor patients' disease improvement when the outcomes are all continuous. This method offers several possible advantages over existing methods for measuring patients' improvement... - Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
Ann Rheum Dis 67:703-9. 2008..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)... - Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trialDinesh Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
J Rheumatol 35:466-8. 2008..We assessed if HAQ-DI scores are different when calculated with and without aids/devices, and if apparent responsiveness changes when scored in these 2 ways... - Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin
University of California at Los Angeles, Los Angeles, USA
N Engl J Med 354:2655-66. 2006.... - Oral cyclophosphamide for active scleroderma lung disease: a decision analysisDinesh Khanna
Division of Rheumatology, School of Public Health, University of California at Los Angeles, Los Angeles, CA 90095, USA
Med Decis Making 28:926-37. 2008..Also, the long-term balance of risk and benefit remains unclear... - High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung diseaseJonathan G Goldin
David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
Chest 134:358-67. 2008..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized... - Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna
David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA
Arthritis Rheum 60:1102-11. 2009.... - Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohortVeena K Ranganath
UCLA, Department of Medicine, Division of Rheumatology, Rehabilitation Center, Room 32 59, 1000 Veteran Avenue, Los Angeles, CA 90095 1670, USA
Ann Rheum Dis 66:1633-40. 2007.... - Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA databaseVeena K Ranganath
Department of Medicine, Division of Rheumatology, UCLA Rehabilitation Center, University of California, Los Angeles, California 90095 1670, USA
J Rheumatol 35:1966-71. 2008.... - Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohortDinesh Khanna
Division of Immunology, Department of Medicine, University of Cincinnati and the Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
Arthritis Rheum 57:440-7. 2007..To evaluate published proposed definitions of minimal disease activity (MDA) and remission in patients with early rheumatoid arthritis (RA)... - Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patientVeena K Ranganath
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90025-1670, USA
Clin Geriatr Med 21:649-69, viii. 2005..There has been some progress in understanding the elderly RA patient, however, there is insufficient data for much confidence in DMARDs effects in the elderly... - Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patientVeena K Ranganath
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, 1000 Veteran Avenue, Room 32 59, Los Angeles, CA 90025 1670, USA
Rheum Dis Clin North Am 33:197-217. 2007..There has been some progress in understanding the elderly RA patient; however, data are insufficient to provide much confidence in DMARDs effects in the elderly... - Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseasesRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 9:583-91. 2003..The differences between equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this regimen without further study... - Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritisMichael H Weisman
Cedars Sinai Medical Center, Los Angeles, California, USA
Arthritis Rheum 54:607-12. 2006..This study investigated whether risk genotypes for folate-dependent enzymes are associated with the toxicity of MTX in patients with rheumatoid arthritis (RA)... - Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritisSogol S Amjadi
Division of Rheumatology, University of California Los Angeles School of Medicine, Department of Health Services, 1000 Veteran Avenue, Room 32 59, Rehabilitation Center, Los Angeles, CA 90095, USA
J Rheumatol 36:1150-7. 2009..We evaluated the construct validity of the HAQ-DI-derived Short Form-6D (SF-6D) score and assessed its responsiveness to change over 6- and 12-month followup periods in patients with early aggressive rheumatoid arthritis (RA)... - Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritisDaniel O Clegg
Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
N Engl J Med 354:795-808. 2006..The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis... - Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritisSteven S Storage
Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA
Korean J Intern Med 25:1-17. 2010..As expected, some adverse events occur when using these drugs and patients need to be watched carefully...
Research Grants
- Provisional Combined Response Index For Patients With Diffuse Systemic SclerosisDaniel Furst; Fiscal Year: 2007..Lay Language: We propose to develop a response criteria for clinical trials in diffuse scleroderma that can facilitate drug development and hopefully, can lead to effective treatments for scleroderma. ..
- Provisional Combined Response Index For Patients With Diffuse Systemic SclerosisDaniel Furst; Fiscal Year: 2007..Lay Language: We propose to develop a response criteria for clinical trials in diffuse scleroderma, that can facilitate drug development and hopefully, can lead to effective treatments for scleroderma. ..